Mineralys (NASDAQ: MLYS) insider files to sell 2,171 shares

Rhea-AI Filing Summary

Mineralys Therapeutics insider plans new stock sale

A holder of Mineralys Therapeutics common stock, identified in the filing as David Rodman, has filed a notice to sell 2,171 shares of common stock through Merrill Lynch on or about February 9, 2026 on the NASDAQ. The aggregate market value of this planned sale is listed as 65,585.91, with 79,139,956 common shares outstanding.

The shares to be sold were acquired the same day via an exercise of employee stock options in a broker-assisted cashless transaction with Mineralys Therapeutics, Inc. Over the prior three months, the same seller completed multiple common stock sales, including 192,715 shares for gross proceeds of 6,749,100.06 on January 5, 2026, along with several smaller transactions on other January 2026 dates.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	2171	65585.91	79139956	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	02/09/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			2171	02/09/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Mineralys Therapeutics (MLYS) Form 144 filing disclose?

The Form 144 discloses a planned sale of Mineralys Therapeutics common stock by holder David Rodman. It details the number of shares to be sold, expected sale date, broker, market value, how the shares were acquired, and recent prior sales.

How many Mineralys Therapeutics (MLYS) shares are planned to be sold?

The filing shows a planned sale of 2,171 shares of Mineralys Therapeutics common stock. These shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value reported as $65,585.91 at the time of the notice.

How were the Mineralys Therapeutics (MLYS) shares in this Form 144 acquired?

The 2,171 shares were acquired on February 9, 2026 through the exercise of employee stock options. The transaction is described as a broker-assisted cashless exercise with Mineralys Therapeutics, Inc. as the issuer of the common stock.

What prior Mineralys Therapeutics (MLYS) stock sales has the filer made recently?

Over the past three months, David Rodman sold several Mineralys common stock blocks, including 192,715 shares on January 5, 2026 for gross proceeds of $6,749,100.06, plus multiple smaller sales on January 2, 9, 12, 13, 14, and 20, 2026.

How many Mineralys Therapeutics (MLYS) shares are outstanding in this filing?

The filing lists 79,139,956 shares of Mineralys Therapeutics common stock outstanding. This figure provides context for the relative size of the 2,171-share planned sale disclosed in the Form 144 notice by the selling security holder.

Which broker and exchange are used for the Mineralys (MLYS) Form 144 sale?

The planned sale will be executed through Merrill Lynch, with the broker’s address given as 225 Liberty Street, New York. The Form 144 specifies that the 2,171 common shares are intended to be sold on the NASDAQ securities exchange on or about February 9, 2026.